Lakewood-Amedex Biotherapeutics Expands Global Intellectual Property Portfolio With Issuance Of Two Patents, One Each In Australia And New Zealand Respectively
Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update
Lakewood-Amedex Biotherapeutics Reports Nu-3 Data And Completes Key Manufacturing Milestones Ahead Of Planned Phase 2 Trial For Diabetic Foot Ulcer Treatment
Lakewood-Amedex Biotherapeutics Inks Agreement To Serve As Contract Research Organization For Professional Education And Research Institute's Upcoming Phase 2 Clinical Program Of Nu-3
Lakewood-Amedex Biotherapeutics Files Prospectus Related To Resale Of Up To 9,647,726 Shares Of Common Stock By Certain Selling Stockholder
Lakewood-Amedex Biotherapeutics Announces Antimicrobial Resistance Data For Its Lead Compound, Nu-3, Which Showed Slightly Increased Minimum Inhibitory Concentration At The End Of The Experiment For E. Coli And Were Unchanged For MRSA
Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
